Last 3.28 MYR
Change Today -0.04 / -1.20%
Volume 96.4K
As of 3:50 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

ccm duopharma biotech bhd (CCMD) Snapshot

Open
3.36
Previous Close
3.32
Day High
3.36
Day Low
3.28
52 Week High
08/26/14 - 3.37
52 Week Low
12/31/14 - 2.40
Market Cap
455.4M
Average Volume 10 Days
212.3K
EPS TTM
0.26
Shares Outstanding
138.9M
EX-Date
05/27/15
P/E TM
12.8x
Dividend
0.19
Dividend Yield
5.34%
Current Stock Chart for CCM DUOPHARMA BIOTECH BHD (CCMD)

Related News

No related news articles were found.

ccm duopharma biotech bhd (CCMD) Related Businessweek News

No Related Businessweek News Found

ccm duopharma biotech bhd (CCMD) Details

CCM Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, imports, and exports pharmaceutical products and medicines in Malaysia. It offers various over the counter products, such as analgesic/anti-pyretics, antibacterial mouthwash products, children’s vitamins, cough preparations, dermatology products, eye drops, first aid dressings, health supplements, pain relievers, and hand sanitizers. The company offers its products in various dosage forms, including tablets, capsules, syrups, oral antibiotics, creams, haemodialysis solutions, sterile irrigation solutions, sterile powder injectables, small volume injectables, dental cartridges, and eye drop preparations. It exports its products to Vietnam, Ethiopia, Sudan, South East Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, Republic of Yemen, Singapore, and Hong Kong. The company was founded in 1979 and is based in Klang, Malaysia. CCM Duopharma Biotech Berhad is a subsidiary of CCM Marketing Sdn. Bhd.

Founded in 1979

ccm duopharma biotech bhd (CCMD) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ccm duopharma biotech bhd (CCMD) Key Developments

CCM Duopharma Biotech Berhad Announces Final Single Tier Dividend, Payable on June 25, 2015

CCM Duopharma Biotech Berhad announced the final single tier dividend of 14.5 sen per ordinary share, payable on June 25, 2015. EX-date is May 27, 2015. Entitlement date is May 29, 2015.

CCM Duopharma Biotech Berhad Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

CCM Duopharma Biotech Berhad reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, revenue was MYR 51,024,000 against MYR 45,734,000 a year ago. The Group's revenue and PBT has improved as compared to last year corresponding period mainly due to increase demand government hospital and export market. Profit from operations was MYR 13,983,000 against MYR 9,138,000 a year ago. Profit before taxation was MYR 13,921,000 against MYR 9,160,000 a year ago. Profit attributable to shareholders of the company was MYR 11,119,000 against MYR 9,313,000 a year ago. Diluted (based on weighted average) earnings per share was 8.01 sen against 6.71 sen a year ago. For the full year, revenue was MYR 176,961,000 against MYR 162,405,000 a year ago. Profit from operations was MYR 46,782,000 against MYR 40,187,000 a year ago. The Group's revenue and PBT has improved as compared to last year corresponding period mainly due to increase demand from Government Hospitals via tender business. Profit before taxation was MYR 46,509,000 against MYR 40,175,000 a year ago. Profit attributable to shareholders of the company was MYR 35,271,000 against MYR 32,275,000 a year ago. Diluted (based on weighted average) earnings per share was 25.41 sen against 23.25 sen a year ago. Net cash generated from operating activities was MYR 36,147,000 against MYR 39,827,000 a year ago. Acquisition of property, plant and equipment was MYR 12,429,000 against MYR 8,842,000 a year ago.

CCM Duopharma Biotech Berhad Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

CCM Duopharma Biotech Berhad announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of MYR 44,819,000 against MYR 40,845,000 a year ago. Profit from operations was MYR 11,397,000 against MYR 9,056,000 a year ago. Profit before tax was MYR 11,287,000 against MYR 9,054,000 a year ago. Profit attributable to shareholders of the company was MYR 8,682,000 against MYR 6,786,000 a year ago. Basic and diluted earnings per share were 6.25 sen against 4.89 sen a year ago. For the nine months, the company reported revenue of MYR 125,937,000 against MYR 116,671,000 a year ago. Profit from operations was MYR 32,800,000 against MYR 31,052 000 a year ago. Profit before tax was MYR 32,589,000 against MYR 31,017,000 a year ago. Profit attributable to shareholders of the company was MYR 24,575,000 against MYR 24,175,000 a year ago. Basic and diluted earnings per share were 17.70 sen against 17.41 sen a year ago. Net cash generated from operating activities was MYR 14,273,000 against MYR 26,773,000 a year ago. Acquisition of property, plant and equipment was MYR 8,552,000 against MYR 7,757,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCMD:MK 3.28 MYR -0.04

CCMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CCMD.
View Industry Companies
 

Industry Analysis

CCMD

Industry Average

Valuation CCMD Industry Range
Price/Earnings 12.5x
Price/Sales 2.5x
Price/Book -- Not Meaningful
Price/Cash Flow 12.6x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CCM DUOPHARMA BIOTECH BHD, please visit www.duopharma.com.my. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.